BioMedNewsBreaks – Way2Grow Biopharma Corp. Enters ‘Next Phase of Life Science Therapeutics’

Way2Grow (“W2G”), a privately held therapeutic corporation existing under the laws of British Columbia, today announced approval of a Health Canada Dealer’s Licence Application. Under the approval, Health Canada issued notice to W2G to complete the construction of a level 8 secure environ and psilocybin production campus. The license and production facility will allow W2G to procure psychedelics as well as propagate, cultivate, harvest and sell psychedelics to pharmacies, clinics and other licenced research facilities for allowable research purposes pursuant to the Controlled Drugs and Substances Act (the “CDSA”). “We are excited to enter this next phase of life science therapeutics, and we believe this unique combination will lead to the highest-quality targeted organic therapeutic products,” said W2G CEO Jamie Filipuzzi. “As we enter this next phase of our company’s evolution, we will focus on building strategic partnerships to help disseminate our psychedelics research and to expand our distribution.”

To view the full press release, visit https://ibn.fm/kIxWz

About Way2Grow Biopharma Corp. (“W2G”)

W2G is a privately held therapeutic company in the life science industry. W2G began with a vision to help patients gain better access to high-quality, consistent, organic therapeutics. To achieve this vision, W2G has developed a consistent growth plan using tissue culture and molecular biology. These methods allow for the standardization of the procedures used to ensure quality and consistency of W2G’s therapeutics. W2G’s extensive research and intellectual property approach are focused on the development of several new plant-based cultivation techniques, hybrid cultivar development, genetic profiling and tissue culture. By developing a molecular breeding and genetics program, W2G can identify new bioactive compounds to determine interaction with specific genes responsible for chronic diseases. For more information, visit the company’s website at www.W2G.ca.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal Q2 2027 Financial Results, Highlights Phase 3 Pipeline Progress

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.…

4 hours ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended…

3 days ago

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Leverages Vertically Integrated Business Model to Drive Growth and Profitability

Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a…

4 days ago

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Positions for Emerging Peptide Market with Focus on Quality, Traceability

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

4 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control

Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and…

5 days ago